Journal of Clinical Oncology, Vol 26, No 12 (April 20), 2008: pp. 2046-2051
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.0707
Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
F. Stephen Hodi, Philip Friedlander, Christopher L. Corless, Michael C. Heinrich, Suzanne Mac Rae, Andrea Kruse, Jyothi Jagannathan, Annick D. Van den Abbeele, Elsa F. Velazquez, George D. Demetri, and David E. Fisher
You have reached the most complete version of this article accessible without further authentication.
More complete versions are available.
Link to article
|
Article topics:
- Oncology..Imatinib Mesylate
- Oncology..Treatment Options for Skin Cancer
- Medicine..Melanoma
- Oncology..Detection/Screening and Prognosis of Skin Cancer
- Medicine..Genes
- Oncology..Early Detection/Screening
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. V. Lillis, J. North, J. T. Vetto, C. L. Corless, K. P. White, and K. K. Lee
Primary Scrotal Melanoma Presenting as a Large, Amelanotic, Exophytic Mass
Arch Dermatol,
September 1, 2009;
145(9):
1071 - 1072.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Woodman, J. C. Trent, K. Stemke-Hale, A. J. Lazar, S. Pricl, G. M. Pavan, M. Fermeglia, Y.N. V. Gopal, D. Yang, D. A. Podoloff, et al.
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Mol. Cancer Ther.,
August 1, 2009;
8(8):
2079 - 2085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gogas, A. M. M. Eggermont, A. Hauschild, P. Hersey, P. Mohr, D. Schadendorf, A. Spatz, and R. Dummer
Biomarkers in melanoma
Ann. Onc.,
August 1, 2009;
20(suppl_6):
vi8 - vi13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hersey, L. Bastholt, V. Chiarion-Sileni, G. Cinat, R. Dummer, A. M. M. Eggermont, E. Espinosa, A. Hauschild, I. Quirt, C. Robert, et al.
Small molecules and targeted therapies in distant metastatic disease
Ann. Onc.,
August 1, 2009;
20(suppl_6):
vi35 - vi40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.K. Wilkins and P.D. Nathan
Review: Therapeutic opportunities in noncutaneous melanoma
Therapeutic Advances in Medical Oncology,
July 1, 2009;
1(1):
29 - 36.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. S.M. Smalley, K. L. Nathanson, and K. T. Flaherty
Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy
Cancer Res.,
April 15, 2009;
69(8):
3241 - 3244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. B. Hofmann, C. S. Kauczok-Vetter, R. Houben, and J. C. Becker
Overexpression of the KIT/SCF in Uveal Melanoma Does Not Translate into Clinical Efficacy of Imatinib Mesylate
Clin. Cancer Res.,
January 1, 2009;
15(1):
324 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Jiang, J. Zhou, N. K. Yuen, C. L. Corless, M. C. Heinrich, J. A. Fletcher, G. D. Demetri, H. R. Widlund, D. E. Fisher, and F. S. Hodi
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Clin. Cancer Res.,
December 1, 2008;
14(23):
7726 - 7732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Beadling, E. Jacobson-Dunlop, F. S. Hodi, C. Le, A. Warrick, J. Patterson, A. Town, A. Harlow, F. Cruz III, S. Azar, et al.
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Clin. Cancer Res.,
November 1, 2008;
14(21):
6821 - 6828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
